Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients

Bekir Hacioglu; Serkan Akin; Ali R Sever; Kadri Altundag

doi:10.2217/fon.15.164

Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients

Future Oncol. 2015 Sep;11(18):2495-7. doi: 10.2217/fon.15.164. Epub 2015 Aug 17.

Authors

Bekir Hacioglu¹, Serkan Akin¹, Ali R Sever², Kadri Altundag¹

Affiliations

¹ Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 Ankara, Turkey.
² Department of Radiology, Hacettepe University School of Medicine, Ankara, Turkey.

PMID: 26278702
DOI: 10.2217/fon.15.164

No abstract available

Keywords: HER2-positive; adjuvant; breast cancer; chemotherapy; complete remission; intratumoral heterogeneity; locally advanced; neoadjuvant; receptors; trastuzumab.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor
Breast Neoplasms / diagnosis
Breast Neoplasms / drug therapy
Breast Neoplasms / genetics*
Breast Neoplasms / mortality
Breast Neoplasms / pathology*
Erb-b2 Receptor Tyrosine Kinases / antagonists & inhibitors
Erb-b2 Receptor Tyrosine Kinases / genetics*
Erb-b2 Receptor Tyrosine Kinases / metabolism
Female
Gene Amplification*
Genetic Heterogeneity*
Humans
Molecular Targeted Therapy
Neoplasm Staging
Prognosis
Treatment Outcome

Substances

Biomarkers, Tumor
Erb-b2 Receptor Tyrosine Kinases